These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 18694370)

  • 41. Our experience on pain palliation of bone metastasis with Sr-89 or Sm-153 in cancer patients resistant to a conventional analgesic therapy. A retrospective study.
    Montesano T; Giacomobono S; Acqualagna G; Colandrea M; Di Nicola A; Travascio L; Giancamerla M; D'Apollo R; Toteda M; Ugolini F; Filesi M; Ronga G
    Clin Ter; 2009; 160(3):193-9. PubMed ID: 19756320
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases.
    Bayouth JE; Macey DJ; Kasi LP; Fossella FV
    J Nucl Med; 1994 Jan; 35(1):63-9. PubMed ID: 7505819
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Analysis of urine samples from metastatic bone cancer patients administered 153Sm-EDTMP.
    Goeckeler WF; Stoneburner LK; Kasi LP; Fossella FV; Price DR; Fordyce WA
    Nucl Med Biol; 1993 Jul; 20(5):657-61. PubMed ID: 8358352
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer.
    Wang RF; Zhang CL; Zhu SL; Zhu M
    Med Princ Pract; 2003; 12(2):97-101. PubMed ID: 12634464
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of samarium Sm 153 lexidronam for the treatment of dogs with primary tumors of the skull: 20 cases (1986-2006).
    Vancil JM; Henry CJ; Milner RJ; McCoig AM; Lattimer JC; Villamil JA; McCaw DL; Bryan JN
    J Am Vet Med Assoc; 2012 Jun; 240(11):1310-5. PubMed ID: 22607597
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [153Sm]EDTMP: a potential therapy for bone cancer pain.
    Holmes RA
    Semin Nucl Med; 1992 Jan; 22(1):41-5. PubMed ID: 1589805
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structural Characterization of Sm(III)(EDTMP).
    Yang Y; Pushie MJ; Cooper DM; Doschak MR
    Mol Pharm; 2015 Nov; 12(11):4108-14. PubMed ID: 26437889
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain.
    Sartor O; Reid RH; Bushnell DL; Quick DP; Ell PJ
    Cancer; 2007 Feb; 109(3):637-43. PubMed ID: 17167764
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Effect of 153Sm-EDTMP on hematopoiesis and vital organs of 93 patients with bone tumor].
    Deng H; Tan T; Mo T; Zhong S; Kuan A; Hu Y
    Hua Xi Yi Ke Da Xue Xue Bao; 1995 Jun; 26(2):155-9. PubMed ID: 7490021
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
    Brenner W; Kampen WU; Kampen AM; Henze E
    J Nucl Med; 2001 Feb; 42(2):230-6. PubMed ID: 11216521
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Incident pain and analgesic consumption decrease after samarium infusion: a pilot study.
    Ripamonti C; Fagnoni E; Campa T; Seregni E; Maccauro M; Bombardieri E
    Support Care Cancer; 2007 Mar; 15(3):339-42. PubMed ID: 16967302
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Samarium-153-EDTMP dosimetry.
    Heggie JC
    J Nucl Med; 1994 Jan; 35(1):191-2. PubMed ID: 8271053
    [No Abstract]   [Full Text] [Related]  

  • 53. ESR dosimetry of 89Sr and 153Sm in bone.
    Kinoshita A; Braga FJ; Graeff CF; Baffa O
    Appl Radiat Isot; 2001 Feb; 54(2):269-74. PubMed ID: 11200888
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A prospective randomized trial: a comparison of the analgesic effect and toxicity of 153Sm radioisotope treatment in monotherapy and combined therapy including local external beam radiotherapy (EBRT) among metastatic castrate resistance prostate cancer (mCRPC) patients with painful bone metastases.
    Baczyk M; Milecki P; Pisarek M; Gut P; Antczak A; Hrab M
    Neoplasma; 2013; 60(3):328-33. PubMed ID: 23374004
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Use of 153Sm-EDTMP to relieve pain from bone metastasis in lung cancer].
    Ratsimanohatra H; Barlesi F; Doddoli C; Robitail S; Gimenez C; Kleisbauer JP; Astoul P
    Rev Mal Respir; 2005 Apr; 22(2 Pt 1):317-20. PubMed ID: 16092169
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High-activity samarium-153-EDTMP therapy in unresectable osteosarcoma.
    Franzius C; Bielack S; Sciuk J; Vollet B; Jürgens H; Schober O
    Nuklearmedizin; 1999; 38(8):337-40. PubMed ID: 10615669
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma.
    Franzius C; Bielack S; Flege S; Eckardt J; Sciuk J; Jürgens H; Schober O
    Nuklearmedizin; 2001 Dec; 40(6):215-20. PubMed ID: 11797510
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia.
    Rodriguez V; Anderson PM; Litzow MR; Erlandson L; Trotz BA; Arndt CA; Khan SP; Wiseman GA
    Leuk Lymphoma; 2006 Aug; 47(8):1583-92. PubMed ID: 16966270
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Myelotoxicity after systemic radionuclide therapy of painful bone metastases with 153Samarium-EDTMP ].
    Dolezal J; Vizd'a J; Cermáková E
    Vnitr Lek; 2003 Mar; 49(3):189-93. PubMed ID: 12728593
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Samarium-153 EDTMP for metastatic bone pain palliation: the impact of europium impurities.
    Kalef-Ezra JA; Valakis ST; Pallada S
    Phys Med; 2015 Feb; 31(1):104-7. PubMed ID: 25454155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.